Physician profile
Thomas C Logan
NPI 1598733008
$2,384.09
in general payments reported to CMS, 2019-2025
14 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $1,007 · 2021: $117 · 2022: $294 · 2023: $158 · 2024: $346 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.08 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $760.71 | 2020-2025 | Inspire |
| Genzyme Corporation | $567.09 | 2021-2025 | |
| Stryker Corporation | $468.51 | 2019-2022 | |
| Glaxosmithkline, LLC. | $131.79 | 2021-2025 | Nucala |
| Optinose US, INC. | $104.60 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $98.99 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $91.80 | 2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $33.11 | 2025 | Hyqvia, Cuvitru |
| Acclarent, INC | $30.87 | 2021 | |
| Siemens Medical Solutions USA, INC. | $26.13 | 2025 | Immulite 1000 Immunoassay System |
| Kerecis Limited | $23.06 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Alk-Abello, INC | $21.57 | 2020 | |
| Aerin Medical INC. | $13.30 | 2022 | |
| Intersect Ent, INC. | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Logan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.